Do you want to read an article? Please log in or register.
Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC
Lung Cancer
RECOMMENDED
Related content
RECOMMENDED
Lung Cancer
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study
Clin Lung Cancer.
Luciani A, Marra A, Toschi L, Cortinovis D, Fava S, Filipazzi V, Tuzi A, Cerea G, Rossi S, Perfetti V, Rossi A, Giannetta L, Sala L, Finocchiaro G, Pizzutilo EG, Carelli S, Agustoni F, Cergnul M, Zonato S, Siena S, Bidoli P, Ferrari D
doi: 10.1016/j.cllc.2020.05.004.
COMMENTED
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis
Lancet Respir Med.
Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V, Piñeyro D, Sanchez-Cespedes M, Girard N, Brevet M, Giroux-Leprieur E, Dumenil C, Pradotto M, Bironzo P, Capelletto E, Novello S, Cortot A, Copin MC, Karachaliou N, Gonzalez-Cao M, Peralta S, Montuenga LM, Gil-Bazo I, Baraibar I, Lozano MD, Varela M, Ruffinelli JC, Palmero R, Nadal E, Moran T, Perez L, Ramos I, Xiao Q, Fernandez AF, Fraga MF, Gut M, Gut I, Teixidó C, Vilariño N, Prat A, Reguart N, Benito A, Garrido P, Barragan I, Emile JF, Rosell R, Brambilla E, Esteller M
doi: 10.1016/S2213-
RECOMMENDED
Lung Cancer
Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lung Cancer
Park K, Özgüroğlu M, Vansteenkiste J, Spigel D, Yang JC, Bajars M, Ruisi M, Manitz J, Barlesi F
doi: 10.1016/j.lungcan.2021.01.026
RECOMMENDED
Lung Cancer
Immune checkpoint inhibitors at any treatment line in advanced NSCLC: Real-world overall survival in a large Italian cohort
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Andreano A, Bergamaschi W, Russo AG
doi: 10.1016/j.lungcan.2021.06.019
Lung Cancer
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
N Engl J Med
Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, Özgüroğlu M, Zou W, Sandler A, Enquist I, Komatsubara K, Deng Y, Kuriki H, Wen X, McCleland M, Mocci S, Jassem J, Spigel DR
doi: 10.1056/NEJMoa1917346
RECOMMENDED
Lung Cancer
Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies
Clin Lung Cancer.
Schulz C, Gandara D, Berardo CG, Rosenthal R, Foo J, Morel C, Ballinger M, Watkins C,
Chu P
doi: 10.1016/j.cllc.
RECOMMENDED
Lung Cancer
Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Lung Cancer
Clarke JM, Patel JD, Robert F, Kio EA, Thara E, Ross Camidge D, Dunbar M, Nuthalapati S, Dinh MH, Bach BA
doi: 10.1016/j.lungcan.2021.09.004
RECOMMENDED
Lung Cancer
PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med
García Campelo MR, Arriola E, Campos Balea B, López-Brea M, Fuentes-Pradera J, de Castro Carpeno J, Aguado C, Pérez Parente D, de Oro Pulido F, Ruiz-Gracia P, Rodríguez-Abreu D
doi: 10.3390/jcm10194583
RECOMMENDED
Lung Cancer
The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Vekens K, Everaert H, Neyns B, Ilsen B, Decoster L
doi: 10.1016/j.cllc.2021.03.001